FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092820110> ?p ?o ?g. }

• W2092820110 endingPage "1132" @default.
• W2092820110 startingPage "1125" @default.
• W2092820110 abstract "To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to determine the pharmacokinetic profile of irinotecan and its metabolites.Patients with fluorouracil-refractory metastatic colorectal cancer received escalating doses of intravenous irinotecan from 40 to 125 mg/m(2) every 2 weeks in combination with a fixed dose of oral Cs (5 mg/kg bid for 3 days). Pharmacokinetic analysis of plasma irinotecan and its metabolites SN38 and SN38G was performed during paired cycles with and without Cs.Thirty-seven patients were treated. Dose-limiting toxicity of grade 4 neutropenia was seen at an irinotecan dose of 125 mg/m(2). There was no grade 4 diarrhea, and only one patient experienced grade 3 diarrhea. Toxicities caused by Cs were generally mild. Pharmacokinetic studies demonstrated that irinotecan clearance was reduced from 13.4 to 5.8 L/h/m(2) and area under the curve (AUC)(0-tn) was increased 2.2-fold by the coadministration of Cs. Similar significant increases in AUC(0-24h) were seen for both SN38 and SN38G (2.2-fold and 2.3-fold, respectively) in the presence of Cs. Antitumor activity was seen at every irinotecan dose level.The maximum tolerated irinotecan dose and recommended dose for phase II studies is 100 mg/m(2) every 2 weeks. Dose-limiting diarrhea was not seen during this study, supporting the hypothesis that pharmacokinetic modulation of irinotecan by Cs may improve its therapeutic index. Further studies using this combination are warranted." @default.
• W2092820110 created "2016-06-24" @default.
• W2092820110 creator A5001923554 @default.
• W2092820110 creator A5022702970 @default.
• W2092820110 creator A5027640771 @default.
• W2092820110 creator A5032238130 @default.
• W2092820110 creator A5032565350 @default.
• W2092820110 creator A5032625382 @default.
• W2092820110 creator A5058562981 @default.
• W2092820110 creator A5070722778 @default.
• W2092820110 creator A5078538101 @default.
• W2092820110 date "2003-03-15" @default.
• W2092820110 modified "2023-10-10" @default.
• W2092820110 title "Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer" @default.
• W2092820110 cites W1596051841 @default.
• W2092820110 cites W1774923611 @default.
• W2092820110 cites W1829549101 @default.
• W2092820110 cites W1865791451 @default.
• W2092820110 cites W1950125084 @default.
• W2092820110 cites W2006587976 @default.
• W2092820110 cites W2006824814 @default.
• W2092820110 cites W2014722248 @default.
• W2092820110 cites W2068224783 @default.
• W2092820110 cites W2083913321 @default.
• W2092820110 cites W2084632548 @default.
• W2092820110 cites W2088610332 @default.
• W2092820110 cites W2091216349 @default.
• W2092820110 cites W2094764170 @default.
• W2092820110 cites W2096122707 @default.
• W2092820110 cites W2128447158 @default.
• W2092820110 cites W2161433518 @default.
• W2092820110 cites W2172761866 @default.
• W2092820110 cites W2199744731 @default.
• W2092820110 cites W2261898534 @default.
• W2092820110 cites W2314927739 @default.
• W2092820110 cites W2344721727 @default.
• W2092820110 cites W4243113925 @default.
• W2092820110 doi "https://doi.org/10.1200/jco.2003.08.049" @default.
• W2092820110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12637480" @default.
• W2092820110 hasPublicationYear "2003" @default.
• W2092820110 type Work @default.
• W2092820110 sameAs 2092820110 @default.
• W2092820110 citedByCount "45" @default.
• W2092820110 countsByYear W20928201102012 @default.
• W2092820110 countsByYear W20928201102013 @default.
• W2092820110 countsByYear W20928201102014 @default.
• W2092820110 countsByYear W20928201102015 @default.
• W2092820110 countsByYear W20928201102016 @default.
• W2092820110 countsByYear W20928201102019 @default.
• W2092820110 countsByYear W20928201102020 @default.
• W2092820110 crossrefType "journal-article" @default.
• W2092820110 hasAuthorship W2092820110A5001923554 @default.
• W2092820110 hasAuthorship W2092820110A5022702970 @default.
• W2092820110 hasAuthorship W2092820110A5027640771 @default.
• W2092820110 hasAuthorship W2092820110A5032238130 @default.
• W2092820110 hasAuthorship W2092820110A5032565350 @default.
• W2092820110 hasAuthorship W2092820110A5032625382 @default.
• W2092820110 hasAuthorship W2092820110A5058562981 @default.
• W2092820110 hasAuthorship W2092820110A5070722778 @default.
• W2092820110 hasAuthorship W2092820110A5078538101 @default.
• W2092820110 hasConcept C112705442 @default.
• W2092820110 hasConcept C121332964 @default.
• W2092820110 hasConcept C121608353 @default.
• W2092820110 hasConcept C126322002 @default.
• W2092820110 hasConcept C142424586 @default.
• W2092820110 hasConcept C2776694085 @default.
• W2092820110 hasConcept C2777063308 @default.
• W2092820110 hasConcept C2779528694 @default.
• W2092820110 hasConcept C2779802037 @default.
• W2092820110 hasConcept C2780259306 @default.
• W2092820110 hasConcept C2780508388 @default.
• W2092820110 hasConcept C29730261 @default.
• W2092820110 hasConcept C526805850 @default.
• W2092820110 hasConcept C71924100 @default.
• W2092820110 hasConcept C76318530 @default.
• W2092820110 hasConcept C87355193 @default.
• W2092820110 hasConcept C90924648 @default.
• W2092820110 hasConcept C98274493 @default.
• W2092820110 hasConceptScore W2092820110C112705442 @default.
• W2092820110 hasConceptScore W2092820110C121332964 @default.
• W2092820110 hasConceptScore W2092820110C121608353 @default.
• W2092820110 hasConceptScore W2092820110C126322002 @default.
• W2092820110 hasConceptScore W2092820110C142424586 @default.
• W2092820110 hasConceptScore W2092820110C2776694085 @default.
• W2092820110 hasConceptScore W2092820110C2777063308 @default.
• W2092820110 hasConceptScore W2092820110C2779528694 @default.
• W2092820110 hasConceptScore W2092820110C2779802037 @default.
• W2092820110 hasConceptScore W2092820110C2780259306 @default.
• W2092820110 hasConceptScore W2092820110C2780508388 @default.
• W2092820110 hasConceptScore W2092820110C29730261 @default.
• W2092820110 hasConceptScore W2092820110C526805850 @default.
• W2092820110 hasConceptScore W2092820110C71924100 @default.
• W2092820110 hasConceptScore W2092820110C76318530 @default.
• W2092820110 hasConceptScore W2092820110C87355193 @default.
• W2092820110 hasConceptScore W2092820110C90924648 @default.
• W2092820110 hasConceptScore W2092820110C98274493 @default.
• W2092820110 hasIssue "6" @default.
• W2092820110 hasLocation W20928201101 @default.

• next